Key Points
- Director Viviane Monges sold 11,969 Pharvaris shares for approximately $395,575 at an average price of $33.05, reducing her direct holdings by 68.52% to 5,500 shares.
- Pharvaris reported quarterly EPS of -$0.81, missing the consensus estimate of -$0.75; analysts expect a full-year loss of approximately $3.12 per share.
- Despite the insider sale, analyst sentiment remains largely positive, with a consensus “Moderate Buy” rating and an average price target of $59.87, compared with the stock’s $32.02 opening price.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Viviane Monges sold 11,969 shares of the business's stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total transaction of $395,575.45. Following the sale, the director directly owned 5,500 shares in the company, valued at $181,775. The trade was a 68.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Pharvaris Stock Performance
Shares of NASDAQ PHVS opened at $32.02 on Friday. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The company has a 50 day simple moving average of $35.29 and a two-hundred day simple moving average of $31.98. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -10.50 and a beta of -2.33.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.
Institutional Trading of Pharvaris
Institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. increased its holdings in shares of Pharvaris by 225.5% in the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock worth $14,068,000 after purchasing an additional 281,829 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Pharvaris in the second quarter worth $26,677,000. Seven Fleet Capital Management LP lifted its holdings in shares of Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock valued at $26,782,000 after purchasing an additional 457,804 shares in the last quarter. Moore Capital Management LP bought a new position in shares of Pharvaris during the second quarter valued at $1,522,000. Finally, Wellington Management Group LLP boosted its position in shares of Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter.
Analysts Set New Price Targets
A number of brokerages have issued reports on PHVS. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research note on Wednesday, September 9th. Wedbush raised their price target on Pharvaris from $42.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Morgan Stanley lifted their price target on Pharvaris from $46.00 to $62.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. Wells Fargo & Company upped their price target on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research report on Friday, July 17th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $59.87.
Check Out Our Latest Research Report on Pharvaris
About Pharvaris
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
